Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc Announces Approval for Manufacturing and Marketing of "Micamlo Combination Tablets BP"


Friday, 21 Dec 2012 01:00am EST 

Astellas Pharma Inc announced that it has obtained approval for manufacturing and marketing of "Micamlo Combination Tablets BP" a combination drug of telmisartan 80 mg, a long-acting angiotensin II type 1 (AT1) receptor blocker (ARB), and amlodipine 5 mg, a long-acting calcium channel blocker. 

Company Quote

1697.5
-11.0 -0.64%
1:00am EST